KRAS and renal cell carcinoma: The latest NCCN clinical practice guidelines for colon cancer state that panitumumab or cetuximab should be used as a first-line treatment for only KRAS wild-type LCC among metastatic CRCs.8,28 According to the results of the present study, the biological function and prognostic value of HOXB13 might apply to only RCC.